Part I – The clinical trial landscape of the Asia-Pacific, Japan

Part I Clinical trial environment in China

Part I – The clinical trial landscape of the Asia-Pacific, Japan

On the heels of our recent post on our presence at this week’s DIA Japan 2015, BBK welcomes Philip Gregory, the General Manager of George Clinical – CRO China as our guest contributor. With more than 20 years of experience in pharmaceutical, biotech and medical device marketing, Mr. Gregory has spent over 14 years supporting the […]

Read More

December 3rd, 2016

New Data shows SGLT2 Inhibitors May be effective in preventing Kidney Failure

New data presented at the American Society of Nephrology meeting in San Diego last November offers new hope to people with diabetes at risk of kidney disease and kidney failure. They suggest a new class of glucose-lowering agents, sodium glucose co-transporter type 2 (SGLT2) inhibitors, may be effective in preventing kidney failure. This data has […]

Read More

November 27th, 2016

Lowering blood pressure to decrease risk of cardiovascular events

Globally, there are millions of people that could benefit from an intensive lowering of blood pressure (BP). An individual with lower BP decreases their chances of suffering from any cardiovascular events such as: stroke, heart disease or heart attacks. A new study shows that lowering blood pressure to less than 140 mm Hg, the current […]

Read More

November 21st, 2016

Diabetes warning signs even healthy women needs to heed

If you haven’t thought about diabetes before, it is time to stop and think for a minute. Why, you might ask? The World Health Organization’s figures from last year estimate over 350 million people worldwide have diabetes. The emerging epidemic is attributed to the rapid increases in overweight, obese and physically inactive individuals. Diabetes is […]

Read More

November 1st, 2016
Clinical research for diabetes and more

Record-setting metrics for Chinese Phase III Diabetes Study

Access to large markets where clinical trials that can investigate real patient needs, and do so in a rapid fashion, is invaluable for clinical research organisations.  One such example of George Clinical rapid and access to huge markets took place in China, where diabetes patients numbered up to 90 million in 2010, and the most […]

Read More

October 20th, 2016

Bad news for saxagliptin?

Recently, the FDA said it will review possible heart risks associated with saxagliptin, a widely used diabetes drug.

Read More

February 13th, 2014

Battling the diabetes epidemic in China

A diabetes epidemic is upon us, despite improved knowledge and therapy on this disease. The recently published 6th edition of the International Diabetes Federation Atlas provides some alarming figures.

Read More

January 7th, 2014

Add George Clinical to your network